Phase 3, Open-label Study Evaluating the Long-term Safety of VX445 Combination Therapy in Subjects with Cystic Fibrosis

This study is being done to learn more about the safety and tolerability of the combination of elexacaftor (VX-445), TEZ and IVA in patients with CF.

Key Eligibility Criteria

Diagnosis of Cystic Fibrosis, Age 18years +

Therapeutic Area

Cystic Fibrosis

Type of Study

Clinical Trial VX18-445-113

Study Status

Not-Recruiting

Sponsor

Vertex Pharmaceuticals

Principal Investigator

Prof Edward McKone

Contact

Brenda.grogan@ucd.ie